News
CuraVac's announcements, milestones and behind-the-scenes.
Pocahontas’ uncle, the first suspected case of Myasthenia Gravis
In the 17th century, Opechancanough led devastating attacks on British settlers. Historical accounts on the powerful chief of the Powhatan Confederacy describe him as a feared warrior, but also mention a mysterious illness that left him exhausted and unable to lift his eyelids.
Read the article
CuraVac Unveils Its New Website
CuraVac is launching a website that reflects who we are: dynamic, accessible, and forward-looking. Explore updated content, a clean yet vibrant design, and new sections designed to help you stay up to date with our latest developments.
Read the article
Teddy the Labradoodle on the Road to Remission with Targeted Active Therapy
In collaboration with Ludwig Maximilian University of Munich, CuraVac has carried out a second compassionate-use administration of its experimental treatment, CV-MG01, in a dog suffering from myasthenia gravis. Six weeks after his first injection, Teddy is walking again.
Read the article
CuraVac Expands into the Veterinary Market
CuraVac is expanding its scope with the official launch of its veterinary unit. The company aims to bring its first treatment for canine myasthenia gravis to market by 2028 and intends for this new activity to become a key driver for the development of its broader therapeutic platform.
Read the article
Celebrating Uto’s Two Years Symptom-Free
In 2024, Uto, a dog suffering from canine myasthenia gravis, successfully completed a 3-dose course of Targeted Active Therapy. He quickly achieved complete remission with no relapse or adverse effects. Let’s celebrate these two years of restored health!
Read the article
The Wall Street Journal — Desperate for a Treatment, One Physician Heals Himself (2010)
Frustrated by Lack of Interest From Drug Companies, a Belgian Doctor Pursues Own Research to Help Cure His Disease
Read the articleNo news yet.
Let's stay in touch
A question, or the will to support us?